XML 176 R118.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Commitments and Contingencies (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2015 | Jun. 30, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2010 | Dec. 31, 2006 | Jun. 30, 2013 | Apr. 02, 2013 | Jan. 31, 2007
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Cancellable future commitments | $ 559.0 |  | $ 559.0 |  |  |  |  |  |  |
Maximum contingent consideration in the form of development and approval milestones | 1,300.0 |  | 1,300.0 |  |  |  |  |  |  |
Increase to goodwill |  |  | 908.1 | $ 527.3 |  |  |  |  |  |
Commitments And Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Lease rent expense which terminates at various dates through 2028 |  |  | 68.6 | 62.4 | $ 56.1 |  |  |  |  |
Liabilities associated with uncertain tax positions | 45.4 |  | 45.4 |  |  |  |  |  |  |
Accrued expenses | 25.0 |  | 25.0 |  |  |  |  |  |  |
Potential future milestone payments commitment, approximately | 2,800.0 |  | 2,800.0 |  |  |  |  |  |  |
TYSABRI product |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Future contingent payment for annual worldwide net sales up to $2.0 billion |  |  |  |  |  |  |  |  | 18.00% |
Future contingent payment threshold |  |  |  |  |  |  |  |  | $ 2,000.0 |
Future contingent payment for annual worldwide net sales that exceed $2.0 billion |  |  |  |  |  |  |  |  | 25.00% |
Biogen Hemophilia |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum contingent consideration in the form of development and approval milestones |  |  |  |  |  |  |  |  |  | $ 80.0
Milestone payments made during period |  | $ 20.0 |  |  |  | $ 40.0 |  |  |  |
Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Amount paid in cash |  |  |  |  |  |  | $ 220.0 |  |  |
Cambridge Leases |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Charges recognized to vacate building |  |  |  |  | $ 27.2 |  |  |  |  |
Solothurn |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Cancellable future commitments | 126.4 |  | 126.4 |  |  |  |  |  |  |
TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum contingent consideration in the form of development and approval milestones |  |  |  |  |  |  |  | $ 15.0 |  |
Increase to goodwill |  |  | 900.0 | $ 600.0 |  |  |  |  |  |
Six billion | TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Amount paid in cash |  |  | 850.0 |  |  |  |  |  |  |
Cumulative sales level | 6,000.0 |  | 6,000.0 |  |  |  |  |  |  |
Four billion | TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Cumulative sales level | 4,000.0 |  | 4,000.0 |  |  |  |  |  |  |
Five billion | TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Cumulative sales level | 5,000.0 |  | 5,000.0 |  |  |  |  |  |  |
Seven billion | TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Increase to goodwill | 300.0 |  |  |  |  |  |  |  |  |
Cumulative sales level | 7,000.0 |  | 7,000.0 |  |  |  |  |  |  |
One billion | TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Cumulative sales level | 1,000.0 |  | 1,000.0 |  |  |  |  |  |  |
Each additional one billion up to twenty billion | TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Increase to goodwill | 300.0 |  |  |  |  |  |  |  |  |
Cumulative sales level | 20,000.0 |  | 20,000.0 |  |  |  |  |  |  |
Three billion | TECFIDERA | Fumapharm AG |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Cumulative sales level | $ 3,000.0 |  | $ 3,000.0 |  |  |  |  |  |  |

X
- Definition Accrued expenses on funding commitment related to clinical research. + References No definition available. + Details
Name: | biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Charges recognized to vacate building + References No definition available. + Details
Name: | biib_Chargesrecognizedtovacatebuilding
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Commitments And Contingencies. + References No definition available. + Details
Name: | biib_CommitmentsAndContingenciesTextualAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative sales level + References No definition available. + Details
Name: | biib_CumulativeSalesLevel
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Future contingent payment for annual worldwide net sales that exceed $2.0 billion + References No definition available. + Details
Name: | biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Future contingent payment for annual worldwide net sales up to $2.0 billion + References No definition available. + Details
Name: | biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Future contingent payment threshold + References No definition available. + Details
Name: | biib_FutureContingentPaymentThreshold
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payments Made During Period. + References No definition available. + Details
Name: | biib_MilestonePaymentsMadeDuringPeriod
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential future milestone payments commitment to third party approximately. + References No definition available. + Details
Name: | biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillAcquiredDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References No definition available. + Details
Name: | us-gaap_LeaseAndRentalExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The current portion of the amount recognized for uncertain tax positions as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_LiabilityForUncertainTaxPositionsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_FacilityLocationAxis=biib_CambridgeLeasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_FacilityLocationAxis=biib_SolothurnMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=biib_TecfideraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_CumulativeSalesLevelAxis=biib_SixbillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_CumulativeSalesLevelAxis=biib_FourbillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_CumulativeSalesLevelAxis=biib_FivebillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_CumulativeSalesLevelAxis=biib_SevenbillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_CumulativeSalesLevelAxis=biib_OneBillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |